{"id":"NCT00824291","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","briefTitle":"Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder","officialTitle":"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate Functional Outcome In Outpatients With Major Depressive Disorder Treated With Desvenlafaxine Succinare Sustained Release","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02","primaryCompletion":"2009-10","completion":"2009-11","firstPosted":"2009-01-16","resultsPosted":"2010-11-25","lastUpdate":"2011-03-10"},"enrollment":437,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder, Major"],"interventions":[{"type":"DRUG","name":"desvenlafaxine succinate sustained release","otherNames":["Pristiq"]},{"type":"GENETIC","name":"Genotyping","otherNames":[]}],"arms":[{"label":"1","type":"PLACEBO_COMPARATOR"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"This is a multicenter study to assess the health and well-being in subjects who are outpatients with major depressive disorder that take desvenlafaxine succinate sustained release (DVS SR) or placebo for 12 weeks.","primaryOutcome":{"measure":"Change From Baseline in Hamilton Depression Scale (HAM-D) at Week 12","timeFrame":"At Baseline and Week 12.","effectByArm":[{"arm":"DVS SR 50 mg","deltaMin":-12.61,"sd":0.45},{"arm":"Placebo","deltaMin":-10.5,"sd":0.6}],"pValues":[{"comp":"OG000 vs OG001","p":"0.002"}]},"eligibility":{"minAge":"19 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["34183490","29140227","27009044","26709542","26644956","25758058","25012446","24583567","24571916"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3151A1-4415&StudyName=Study%20Evaluating%20Desvenlafaxine%20Succinate%20Sustained%20Release%20In%20Outpatients%20With%20Major%20Depressive%20Disorder"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":285},"commonTop":["Nausea","Headache","Dry mouth","Dizziness","Constipation"]}}